Search Here

Pamela Arterbridge, a 46-year-old patient diagnosed with Relapsing-Remitting Multiple Sclerosis, took part in a clinical medicine, ocrevus trial, and says that she's feeling great than ever.

Multiple Sclerosis, which also has a certain type called Relapsing-Remitting Multiple Sclerosis (RMS), is a condition which affects the brain and spinal cord, with symptoms of tingling, blurred vision, weakness, urinary problems and muscle stiffness, the WebMD sheds light.

Medical treatments like injectable medicines and oral pills have been floating around to relieve symptoms and delay the progression of the disease.

The Ohio State University's Multiple Sclerosis Center had an open-label clinical trial on Ocrelizumab, best known as ocrevus. Arterbridge, who is a patient of the Dr. Micheal Racke, is one of the 70 people taking part in the trial.

The ocrevus drug has been approved by the U.S. Food and Drug Administration as the first B-cell therapy. The trial is a pioneer in the field of B-cell treatments fro Multiple Sclerosis, the Multiple Sclerosis News Today reports.

The process in a humanized monoclonal antibody and is administered every six weeks through infusion. Pamela has had three infusions of ocrelizumab already and she says that she is feeling so much better. The symptoms seem to be just minimal compared to the previous ones that caused her so much pain and inconvenience.

Pamela Arterbridge shares that ocrevus was not the first treatment prescribed to her. She went through injecting herself three times a week to better her conditions but those gave her huge bruises and site reactions that led to burning pain. She said it was too much of a hassle since she has been rushed to the ER, for several occasions already, to be treated for the side-effects of the drug she has been using before.

With FDA's approval of the drug, Pamela said that she's happy that people with condition same as hers, could also benefit from the help ocrevus brings.